Influenza

BMJ (Online)

Volumn 355, Issue , 2016, Pages

  Ghebrehewet, Sam ^a   Macpherson, Peter ^a,b,c   Ho, Antonia ^b,d  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^d QUEEN ELIZABETH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIPYRETIC AGENT; ARBIDOL; FAVIPIRAVIR; INFLUENZA VACCINE; NITAZOXANIDE; OSELTAMIVIR; PLACEBO; ZANAMIVIR; ANTIVIRUS AGENT;

ARTICLE; BACTERIAL INFECTION; COLD LIKE SYMPTOM; COMMON COLD SYMPTOM; COUGHING; DRUG CONTRAINDICATION; DRUG EFFICACY; EPIDEMIC; FEVER; FLUID INTAKE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; IMMUNOFLUORESCENCE TEST; INFECTION CONTROL; INFLUENZA; INFLUENZA A; INFLUENZA A RAPID TEST; INFLUENZA VACCINATION; INJECTION SITE REACTION; MALAISE; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; MYALGIA; NOSE OBSTRUCTION; PANDEMIC INFLUENZA; POLYMERASE CHAIN REACTION; POST EXPOSURE PROPHYLAXIS; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REST; SORE THROAT; SYMPTOMATOLOGY; VIRUS SHEDDING; VULNERABLE POPULATION; HOSPITALIZATION; INFLUENZA, HUMAN; PANDEMIC; RISK ASSESSMENT;

ANTIVIRAL AGENTS; EPIDEMICS; HOSPITALIZATION; HUMANS; INFECTION CONTROL; INFLUENZA VACCINES; INFLUENZA, HUMAN; PANDEMICS; POST-EXPOSURE PROPHYLAXIS; RISK ASSESSMENT;

EID: 85006055013     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i6258     Document Type: Article

References (62)

1. World Health Organization. Influenza (seasonal)-Fact sheet No 211. 2014. www.who. int/mediacentre/factsheets/fs211/en/.
2. Cromer D, van Hoek AJ, Jit M, Edmunds WJ, Fleming D, Miller E. The burden of influenza in England by age and clinical risk group: a statistical analysis to inform vaccine policy. J Infect 2014;68:363-71. doi:10.1016/j.jinf.2013.11.013 pmid:24291062
3. World Health Organization. Global Influenza Surveillance and Response System (GISRS). 2016. www.who.int/influenza/gisrs
4. World Health Organization. Influenza vaccine viruses and reagents. 2016. www.who.int/influenza/vaccines/virus/en/.
5. Ferguson L, Eckard L, Epperson WB, et al. Influenza D virus infection in Mississippi beef cattle. Virology 2015;486:28-34. doi:10.1016/j.virol.2015.08.030 pmid:26386554
6. Hause BM, Collin EA, Liu R, et al. Characterization of a novel influenza virus in cattle and Swine: proposal for a new genus in the Orthomyxoviridae family. MBio 2014;5:e00031-14. doi:10.1128/mBio.00031-14 pmid:24595369
7. A revision of the system of nomenclature for influenza viruses: a WHO memorandum. Bull World Health Organ 1980;58:585-91.pmid:6969132
8. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol Rev 1992;56:152-79.pmid:1579108
9. Olson DR, Heffernan RT, Paladini M, Konty K, Weiss D, Mostashari F. Monitoring the impact of influenza by age: emergency department fever and respiratory complaint surveillance in New York City. PLoS Med 2007;4:e247. doi:10.1371/journal.pmed. 0040247 pmid:17683196
10. Kawai S, Nanri S, Ban E, et al. Influenza vaccination of schoolchildren and influenza outbreaks in a school. Clin Infect Dis 2011;53:130-6. doi:10.1093/cid/cir336 pmid: 21690619
11. Matsuzaki Y, Sugawara K, Furuse Y, et al. Genetic Lineage and Reassortment of Influenza C Viruses Circulating between 1947 and 2014. J Virol 2016;90:8251-65. doi:10.1128/JVI. 00969-16 pmid:27384661
12. Public Health England. PHE guidance on use of antiviral agents for the treatment and prophylaxis of seasonal influenza. Version 7.0. PHE, 2016
13. Lam PP, Coleman BL, Green K, et al. Predictors of influenza among older adults in the emergency department. BMC Infect Dis 2016;16:615. doi:10.1186/s12879-016-1966-4 pmid:27793117
14. Monto AS, Gravenstein S, Elliott M, Colopy M, Schweinle J. Clinical signs and symptoms predicting influenza infection. Arch Intern Med 2000;160:3243-7. doi:10.1001/archinte. 160.21.3243 pmid:11088084
15. Ohmit SE, Monto AS. Symptomatic predictors of influenza virus positivity in children during the influenza season. Clin Infect Dis 2006;43:564-8. doi:10.1086/506352 pmid:16886147
16. Minodier L, Charrel RN, Ceccaldi PE, et al. Prevalence of gastrointestinal symptoms in patients with influenza, clinical significance, and pathophysiology of human influenza viruses in faecal samples: what do we know?Virol J 2015;12:215. doi:10.1186/s12985-015-0448-4 pmid:26651485
17. Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DA. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis 2009;9:291-300. doi:10.1016/S1473-3099(09)70069-6 pmid:19393959
18. Department of Health. Routes of transmission of the influenza virus: scientific evidence base review. DoH, 2011
19. Killingley B, Greatorex J, Digard P, et al. The environmental deposition of influenza virus from patients infected with influenza A(H1N1)pdm09: Implications for infection prevention and control. J Infect Public Health 2016;9:278-88. doi:10.1016/j.jiph.2015.10.009 pmid: 26653976
20. Lau LLH, Cowling BJ, Fang VJ, et al. Viral shedding and clinical illness in naturally acquired influenza virus infections. J Infect Dis 2010;201:1509-16. doi:10.1086/652241 pmid: 20377412
21. National Institute for Health and Care Excellence. Clinical Knowledge Summaries: Influenza-seasonal. 2015. https://cks.nice.org.uk/influenza-seasonal
22. National Institute for Health and Care Excellence. Amantadine, oseltamivir and zanamivir for the treatment of influenza (technology appraisal guidance 168). 2009. www.nice.org. uk/Guidance/ta168
23. Public Health England. Chapter 19: Influenza. In: Immunisation Against Infectious Disease. 2013, updated 2015. www.gov.uk/government/uploads/system/uploads/attachment-data/file/456568/2904394-Green-Book-Chapter-19-v10-0.pdf
24. Viboud C, Alonso WJ, Simonsen L. Influenza in tropical regions. PLoS Med 2006;3:e89. doi:10.1371/journal.pmed.0030089 pmid:16509764
25. Moura FE. Influenza in the tropics. Curr Opin Infect Dis 2010;23:415-20. doi:10.1097/QCO.0b013e32833cc955 pmid:20644472
26. World Health Organization. Pandemic influenza preparedness and response. WHO, 2010
27. Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2014;4:CD008965.pmid:24718923
28. Muthuri SG, Venkatesan S, Myles PR, et al. PRIDE Consortium Investigators. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014;2:395-404. doi:10.1016/S2213-2600(14)70041-4 pmid:24815805
29. Zambon M. Developments in the treatment of severe influenza: lessons from the pandemic of 2009 and new prospects for therapy. Curr Opin Infect Dis 2014;27:560-5. doi:10.1097/QCO.0000000000000113 pmid:25333476
30. Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 2015;385:1729-37. doi:10.1016/S0140-6736(14)62449-1 pmid:25640810
31. Department of Health. Chief Medical Officer and Chief Pharmaceutical Officer: advice on using antiviral medicines: influenza season 2015 to 2016. DoH, 2016
32. World Health Organization. WHO Guidelines for pharmacological management of pandemic influenza A(H1N1) 2009 and other influenza viruses. WHO, 2010
33. Demicheli V, Jefferson T, Al-Ansary LA, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2014;3:CD001269.pmid:24623315
34. Kliner M, Keenan A, Sinclair D, Ghebrehewet S, Garner P. Influenza vaccination for healthcare workers in the UK: appraisal of systematic reviews and policy options. BMJ Open 2016;6:e012149. doi:10.1136/bmjopen-2016-012149 pmid:27625062
35. Beran J, Peeters M, Dewé W, Raupachov J, Hobzov L, Devaster JM. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults. BMC Infect Dis 2013;13:224. doi:10.1186/1471-2334-13-224 pmid: 23688546
36. Kieninger D, Sheldon E, Lin WY, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged =18 years. BMC Infect Dis 2013;13:343. doi:10.1186/1471-2334-13-343 pmid:23883186
37. Pépin S, Donazzolo Y, Jambrecina A, Salamand C, Saville M. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Vaccine 2013;31:5572-8. doi:10. 1016/j.vaccine.2013.08.069 pmid:24016810
38. Tinoco JC, Pavia-Ruz N, Cruz-Valdez A, et al. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged =18 years: a phase III, randomized trial. Vaccine 2014;32:1480-7. doi:10.1016/j.vaccine.2014.01.022 pmid:24486352
39. Baguelin M, Flasche S, Camacho A, Demiris N, Miller E, Edmunds WJ. Assessing optimal target populations for influenza vaccination programmes: an evidence synthesis and modelling study. PLoS Med 2013;10:e1001527. doi:10.1371/journal.pmed.1001527 pmid: 24115913
40. Loeb M, Russell ML, Moss L, et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA 2010;303:943-50. doi:10.1001/jama.2010.250 pmid:20215608
41. Belshe RB, Edwards KM, Vesikari T, et al. CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007;356:685-96. doi:10.1056/NEJMoa065368 pmid:17301299
42. Fleming DM, Crovari P, Wahn U, et al. CAIV-T Asthma Study Group. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006;25:860-9. doi:10.1097/01.inf.0000237797.14283.cf pmid:17006278
43. Ambrose CS, Luke C, Coelingh K. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. Influenza Other Respir Viruses 2008;2:193-202. doi:10.1111/j.1750-2659.2008.00056.x pmid:19453395
44. Englund JA, Mbawuike IN, Hammill H, Holleman MC, Baxter BD, Glezen WP. Maternal immunization with influenza or tetanus toxoid vaccine for passive antibody protection in young infants. J Infect Dis 1993;168:647-56. doi:10.1093/infdis/168.3.647 pmid:8354906
45. Zaman K, Roy E, Arifeen SE, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008;359:1555-64. doi:10.1056/NEJMoa0708630 pmid: 18799552
46. Naleway AL, Irving SA, Henninger ML, et al. Vaccine Safety Datalink and Pregnancy and Influenza Project. Safety of influenza vaccination during pregnancy: a review of subsequent maternal obstetric events and findings from two recent cohort studies. Vaccine 2014;32:3122-7. doi:10.1016/j.vaccine.2014.04.021 pmid:24742490
47. Tamma PD, Ault KA, del Rio C, Steinhoff MC, Halsey NA, Omer SB. Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol 2009;201:547-52. doi:10.1016/j.ajog. 2009.09.034 pmid:19850275
48. National Institute for Health and Care Excellence. Oseltamivir, amantadine and zanamivir for the prophylaxis of influenza (technology appraisal guidance 158). 2008. www.nice.org. uk/guidance/ta158
49. Public Health England. Infection control precautions to minimise transmission of respiratory tract infections (RTIs) in the healthcare setting. PHE, 2014
50. Siegel J, Rhinehart E, Jackson M, Centers for Disease Control and Prevention. Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings. CDC, 2007
51. Health and Safety Executive. Pandemic flu-workplace guidance. HSE, 2016
52. European Centre for Disease Prevention and Control (ECDC). Technical document. Safe use of personal protective equipment in the treatment of infectious diseases of high consequence: A tutorial for trainers in healthcare settings. Version 2, 2014
53. Public Health England. PHE guidelines on the management of outbreaks of influenza-like illness in care homes. 2016. www.gov.uk/government/publications/acute-respiratorydisease-managing-outbreaks-in-care-homes
54. Public Health England. Managing outbreaks of acute respiratory disease in care homes. 2012 (and supplement 2014). www.gov.uk/government/publications/acute-respiratorydisease-managing-outbreaks-in-care-homes
55. Impagliazzo A, Milder F, Kuipers H, et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 2015;349:1301-6. doi:10.1126/science. aac7263 pmid:26303961
56. Yassine HM, Boyington JC, McTamney PM, et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med 2015;21:1065-70. doi:10.1038/nm.3927 pmid:26301691
57. Joyce MG, Wheatley AK, Thomas PV, et al. NISC Comparative Sequencing Program. Vaccine-induced antibodies that neutralize group 1 and group 2 influenza A viruses. Cell 2016;166:609-23. doi:10.1016/j.cell.2016.06.043 pmid:27453470
58. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013;100:446-54. doi:10.1016/j. antiviral.2013.09.015 pmid:24084488
59. Rossignol JF, La Frazia S, Chiappa L, Ciucci A, Santoro MG. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem 2009;284:29798-808. doi:10.1074/jbc.M109.029470 pmid:19638339
60. Haffizulla J, Hartman A, Hoppers M, et al. US Nitazoxanide Influenza Clinical Study Group. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis 2014;14:609-18. doi:10.1016/S1473-3099(14)70717-0 pmid:24852376
61. Leneva IA, Russell RJ, Boriskin YS, Hay AJ. Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol. Antiviral Res 2009;81:132-40. doi:10.1016/j.antiviral.2008.10.009 pmid:19028526
62. Pécheur EI, Borisevich V, Halfmann P, et al. The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses. J Virol 2016;90:3086-92. doi:10.1128/JVI.02077-15 pmid:26739045